Name: CBIO Income Statement - Crescent Biopharma Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

CBIO - Crescent Biopharma, Inc.

USD | NASDAQ | Healthcare

CBIO Income Statement - Crescent Biopharma Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q4 FY 16	Q3 FY 16	Q2 FY 16
Revenues
Revenues	1.0	-	-	-	0.0	-	-	-	-	-	-	-	-	-	-	0.1

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012
Revenues
Revenues	-	10.8	-	0.0	0.1	1.2	10.2	-	-	-	0.0	20.1	15.0	4.0	15.3
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses
Research & Development	145.4	138.1	14.3	20.1	28.4	47.5	44.9	47.0	40.1	24.1	23.3	25.1	19.6	11.7	9.4
Operating Income
Operating Income	(163.1)	(152.6)	(40.0)	(39.3)	(47.4)	(63.4)	(51.5)	(61.4)	(51.5)	(33.9)	(31.9)	(12.8)	(11.1)	(10.6)
Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Tax & Net
Income Tax Expense	2.0	2.0	-	-	-	-	-	-	-	-	-	-	-	-	-
Per Share
EPS Basic	-	-	(0.59)	(0.58)	(0.89)	(1.23)	(1.12)	(1.34)	-	-	-	-	(0.60)	(8.87)	3.93
EPS Diluted
Supplementary Data
EBITDA	-	(152.5)	(40.0)	(39.1)	(47.2)	(63.2)	(51.2)	(61.1)	(51.2)	(33.7)	(31.7)	(12.6)	(11.0)	(10.5)	3.7
EBIT

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	17.9	95.0	20.3	12.1	10.6	0.2	1.7	6.3	6.0	5.3	5.3	4.1	5.4	5.9	4.9	8.0	9.6	12.9	13.3	10.2	11.1	11.7	10.7	9.9	12.7	11.5	10.7	13.1	11.8	11.8	9.7	9.3	9.3	6.7	5.8	5.7	5.9	6.1	5.9	5.8
Selling General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	7.9	7.3	5.5	8.9	3.6	5.1	4.0	4.1	5.1	4.3	4.5	4.9	5.5	4.7	3.8	5.5	5.1
Depreciation & Amortization	0.1	-	-	-	0.0	-	-	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Amortization of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	25.8	102.3	25.9	21.0	14.2	7.3	11.2	10.4	11.1	9.6	9.8	8.9	10.9	10.6	8.8	13.4

Operating Income
Operating Income	(24.7)	(91.5)	(25.9)	(21.0)	(14.2)	(7.3)	(11.2)	(10.4)	(11.1)	(9.6)	(9.8)	(8.9)	(10.9)	(10.6)	(8.8)	(13.4)	(14.7)	(17.4)	(17.3)	(14.4)	(14.3)	(15.6)	(13.7)	(14.1)	(8.1)	(15.3)	(14.1)	(16.8)	(15.1)	(14.7)	(12.5)	(12.1)	(12.1)	(9.5)	(8.2)	(8.2)	(8.0)	(8.4)	(7.9)	(8.1)

Tax & Net
Income Tax Expense	0.0	2.0	0.0	0.0	0.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	(23.3)	(105.2)	(24.6)	(21.8)	(2.3)	(7.2)	(9.8)	(10.1)	(10.7)	(9.1)	(9.2)	(8.3)	(10.4)	(10.2)	(8.5)	(13.3)	(14.7)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(23.3)	(105.2)	(24.6)	(21.8)	(2.3)	(7.2)	(9.8)	(10.1)	(10.7)	(9.1)	(9.2)	(8.3)	(10.4)	(10.2)	(8.5)	(13.3)	(14.7)
Net Income Attributable To Parent	(23.3)	(92.4)	(24.6)	(21.8)	(15.1)	(7.2)	(9.8)	(10.1)	(10.7)	(9.1)	(9.2)	(8.3)	(10.4)	(10.2)	(8.5)	(13.3)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(21.3)	(78.3)	(20.9)	(19.0)	(15.1)	(7.2)	(9.8)	(10.1)	(10.7)	(9.1)	(9.2)	(8.3)	(10.4)	(10.2)	(8.5)

Per Share
EPS Basic	-	-	-	-	(0.04)	-	(0.15)	(0.16)	(0.17)	-	(0.14)	(0.13)	(0.17)	-	(0.16)	(0.25)	(0.28)	-	(0.34)	(0.28)	(0.28)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(0.41)
EPS Diluted	-	-	-	-	-	-	(0.15)	(0.16)	(0.04)	-	(0.14)	(0.13)	(0.17)	-	(0.16)	(0.25)	(0.28)	-
Shares Basic	-	-	-	-	64.5	-	64.5	64.5	64.5	-	64.3	64.3	60.4	-	52.4	52.4	52.3	-
Shares Diluted	-	-	-	-	-	-	64.5	64.5	64.5	-	64.3	64.3	64.5	-	52.4	52.4	52.3	-

Supplementary Data
EBITDA	(24.7)	-	-	-	(14.2)	-	-	-	(11.1)	(9.6)	(9.8)	(8.9)	(10.9)	(10.6)	(8.7)	(13.3)	(14.6)	(17.4)	(17.3)	(14.3)	(14.2)	(15.5)	(13.7)	(14.0)	(8.0)	(15.3)	(14.0)	(16.7)	(15.1)	(14.6)	(12.5)	(12.1)	(12.1)	(9.5)	(8.1)	(8.2)	(7.9)	(8.3)	(7.8)	(8.0)
EBIT	(24.7)	(91.5)	(25.9)	(21.0)	(14.2)	(7.3)	(11.2)	(10.4)	(11.1)	(9.6)	(9.8)	(8.9)	(10.9)	(10.6)	(8.8)	(13.4)	(14.7)	(17.4)	(17.3)

Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	0.0	0.0	0.0	1.1	1.1	-	-	-	-	-	-	-	-	-	-	-	-	-
Income From Equity Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Income	1.4	-	1.3	(0.8)	(0.9)	-	1.4	-	-	-	0.6	-	-	-	-	-	-
Pre-Tax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-